Posted by Michael Wonder on 04 Oct 2025
Alzinova receives fast track designation from US FDA for ALZ-101 in Alzheimer’s disease
4 October 2025 - Alzinova today announces that the US FDA has granted fast track designation for the company’s vaccine candidate ALZ-101 in Alzheimer’s disease.
Alzinova AB is a Swedish biopharmaceutical company in clinical development specialising in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers.
